Skip to content

Food and Drug Recall.org

The Latest Food & Drug Recall and Safety News

FDA approves new treatment for moderately to severely active ulcerative colitis

May 30, 2018Drug Recalls & Safety Notices, Drug Safety Information Podcasts, Food & Drug Recalls, Food Safety Newsadmin

FDA today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis.

Post navigation

← As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion Statement from FDA Commissioner Scott Gottlieb, M.D., on the signing of the Right to Try Act →
Proudly powered by WordPress